Abstract:The methods currently used for the detection of ANA have been analyzed, with emphasis on their practical application to the diagnosis of the CTD. The use of the indirect IF-ANA test was recommended as a screening procedure to detect ANA. The need to standardize the technique using a single substrate and fluorescent conjugates with uniform F/P ratios was stressed. Most importantly, the value of titrating ANA for the diagnosis of the CTD was discussed. ANA titers higher than 1/500 are usually very significant clinically, often found in spontaneous or drug-induced SLE and few other CTD. The immunologic aspects of ANA and their potential value as aids in the diagnosis and management of the CTD were discussed. Anti-nDNA antibodies have been found to have a high degree of specificity for SLE and high titers of these antibodies correlate well with low levels of serum complement and severity of kidney involvement. The spectrum of ANA in the sera from patients with SLE has been expanded with the finding of anti-Sm antibodies which, when detected by gel precipitation with prototype serum, have been found so far only in SLE. Some of these antibodies have been found to have prognostic significance. Patients with MCTD and a group of patients with SLE have high titers of serum ANA with specificity for an RNase-sensitive component of ENA. The group of SLE patients defined by the presence of these antibodies (anti-Mo) have a better prognosis and in general develop only mild nephritis or have no kidney involvement at all. High titers of pure antinucleolar antibodies probably are found almost exclusively in the sera of patients with scleroderma. Some ANA have organ specificity, and GS-ANA have been found in all patients with Felty's syndrome and in a large proportion of patients with RA. One of the great advances in the field has been the recognition that ANA can be induced in the human and in experimental animals by the use of a number of therapeutic agents. Some of these agents can also induce a clinical picture resembling spontaneous SLE, though kidney involvement does not occur or is extremely mild. It is interesting that the whole spectrum of ANA can be found in drug-induced LE except anti-nDNA antibodies which have been associated to the pathogenesis of immune complex nephritis in spontaneous SLE. There is no doubt that research on ANA has contributed a great deal to the understanding of the CTD and will continue to be a valuable tool for the clinician and the investigator.

Hep-2 cell based indirect immunofluorescence assay for antinuclear antibodies as a potential diagnosis of drug-induced autoimmunity in nonclinical toxicity testing.

[Detection of anti-nuclear antibodies in liver diseases by indirect immunofluorescence method and enzyme-linked immunosorbent assay]

Investigation and analysis of HEp 2 indirect immunofluorescence titers and patterns in various liver diseases

Evaluation strategy of anti-mitochondrial antibodies M2-negative: the role of multiplex rodent tissues and related clinical implications

Antinuclear Antibodies Detection: A Comparative Study Between Automated Recognition and Conventional Visual Interpretation

Detection of antinuclear antibodies: recommendations from EFLM, EASI and ICAP

Utility of Antinuclear Antibody Screening by Various Methods in a Clinical Laboratory Patient Cohort

Performance characteristics and clinical utility of a hybrid ELISA for detection of ANA

How should a district general hospital immunology service screen for anti-nuclear antibodies? An 'in-the-field' audit

Novel autoimmune hepatitis-specific autoantigens identified using protein microarray technology.

Automated Antinuclear Immunofluorescence Antibody Analysis is a Reliable Approach in Routine Clinical Laboratories

Fully automated chemiluminescence microarray immunoassay for detection of antinuclear antibodies in systemic autoimmune rheumatic diseases

Antinuclear antibody screening in this new millennium: farewell to the microscope?

Antinuclear Antibodies in Healthy Population: Positive Association with Abnormal Tissue Metabolism, Inflammation and Immune Dysfunction

Autoantibody profiling of Chinese patients with autoimmune hepatitis using immunoproteomic analysis.

EUROPattern auto-reading system for the determination of anti-nuclear antibody

Antinuclear antibody (ANA) status predicts immune-related adverse events in liver cancer patients undergoing anti-PD-1 therapy.

Application of ANAs Protein Chip in Autoantibodies Proffie Detection

Antinuclear antibodies (ANA): immunologic and clinical significance

Evaluation of autoimmune liver disease antibodies in hepatitis patients

[Detection and the Production Mechanism of Antinuclear Antibodies (ANA) and Anti-Liver/kidney Microsomal Tpe 1 Antibodies (Anti-Lkm1) in Patients with Chronic Hepatitis C].